VEGFA and head and neck squamous cell carcinoma: Cabozantinib does have other immunomodulatory targets besides VEGF (TAM, MER, cMET) and could possibly result in a stronger combinatorial effect with PD-1 inhibitors in a disease such as SCCHN (47).